NCT02160626View on ClinicalTrials.gov

Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Seborrheic Keratosis
Interventions
DRUG

A-101 Vehicle

Placebo control

DRUG

A-101 (40) Topical Solution

A-101 (40) Topical Solution - high dose

DRUG

A-101 (32.5) Topical Solution

A-101 (32.5) Topical Solution - low dose

Trial Locations (5)

24501

The Education & Research Foundation, Inc., Lynchburg

30078

Gwinnett Clinical Research Center, Inc., Snellville

48038

Michigan Center for Research Corp., Clinton Township

78759

DermReseach, Inc., Austin

97223

Oregon Medical Research Center, Portland

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT02160626 - Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis | Biotech Hunter | Biotech Hunter